Education
About Us
Working with TipRanks
Follow Us
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Total Valuation
Wuxi Biologics (Cayman) has a market cap or net worth of $98.14B. The enterprise value is HK$85.25B.
Market Cap$98.14B
Enterprise ValueHK$85.25B
Share Statistics
Wuxi Biologics (Cayman) has 4,063,959,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,063,959,500
Owned by Insiders―
Owned by Institutions0.02%
Financial Efficiency
Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 7.96%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.96%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee1.49M
Profits Per Employee384.45K
Employee Count12,575
Asset Turnover0.33
Inventory Turnover7.25
Valuation Ratios
The current PE Ratio of Wuxi Biologics (Cayman) is 20.06. Wuxi Biologics (Cayman)’s PEG ratio is -1.61.
PE Ratio20.06
PS Ratio0.00
PB Ratio2.21
Price to Fair Value1.61
Price to FCF-255.55
Price to Operating Cash Flow25.44
PEG Ratio-1.61
Income Statement
In the last 12 months, Wuxi Biologics (Cayman) had revenue of 18.68B and earned 3.36B in profits. Earnings per share was 0.89.
Revenue18.68B
Gross Profit7.65B
Operating Income4.97B
Pretax Income4.83B
Net Income3.36B
EBITDA6.43B
Earnings Per Share (EPS)0.89
Cash Flow
In the last 12 months, operating cash flow was 3.64B and capital expenditures -3.98B, giving a free cash flow of -346.67M billion.
Operating Cash Flow3.64B
Free Cash Flow-346.67M
Free Cash Flow per Share-0.09
Dividends & Yields
Wuxi Biologics (Cayman) pays an annual dividend of HK$0.055, resulting in a dividend yield of ―
Dividend Per ShareHK$0.055
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.75
52-Week Price Change86.72%
50-Day Moving Average23.68
200-Day Moving Average18.08
Relative Strength Index (RSI)59.78
Average Volume (3m)45.87M
Important Dates
Wuxi Biologics (Cayman) upcoming earnings date is Aug 25, 2025, TBA Not Confirmed.
Last Earnings DateMar 25, 2025
Next Earnings DateAug 25, 2025
Ex-Dividend DateNov 02, 2023
Financial Position
Wuxi Biologics (Cayman) as a current ratio of 2.73, with Debt / Equity ratio of 11.81%
Current Ratio2.73
Quick Ratio2.56
Debt to Market Cap0.04
Net Debt to EBITDA-0.52
Interest Coverage Ratio31.56
Taxes
In the past 12 months, Wuxi Biologics (Cayman) has paid 889.03M in taxes.
Income Tax889.03M
Effective Tax Rate0.18
Enterprise Valuation
Wuxi Biologics (Cayman) EV to EBITDA ratio is 9.95, with an EV/FCF ratio of 49.69.
EV to Sales3.43
EV to EBITDA9.95
EV to Free Cash Flow49.69
EV to Operating Cash Flow12.26
Balance Sheet
Wuxi Biologics (Cayman) has $9.53B in cash and marketable securities with ¥4.57B in debt, giving a net cash position of -$4.96B billion.
Cash & Marketable Securities$9.53B
Total Debt¥4.57B
Net Cash-$4.96B
Net Cash Per Share-$1.22
Tangible Book Value Per Share$10.66
Margins
Gross margin is 38.66%, with operating margin of 26.63%, and net profit margin of 17.97%.
Gross Margin38.66%
Operating Margin26.63%
Pretax Margin25.89%
Net Profit Margin17.97%
EBITDA Margin34.43%
EBIT Margin26.73%
Analyst Forecast
The average price target for Wuxi Biologics (Cayman) is $31.14, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$31.14
Price Target Upside26.09% Upside
Analyst ConsensusModerate Buy
Analyst Count10
Revenue Growth Forecast7.52%
EPS Growth Forecast-1.92%